Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211988 · ClinicalTrials.gov registry record · Phase 2
Entinostat Neuroendocrine (NE) Tumor
A Phase 2 study, sponsored by Antonio Fojo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03211988 is a Phase 2 study that was terminated before completion, run by Antonio Fojo. The registered enrollment target is 5 participants.
The verdict
NCT03211988, a Phase 2 study, was terminated before completion, sponsored by Antonio Fojo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open-label, single arm, multi-center Phase II trial of entinostat given as a 5 mg oral dose every week (days 1, 8, 15, and 22 of a 4-week cycle) in patients with relapsed or refractory abdominal neuroendocrine (NE) tumors. Patients will continue on treatment until disease progression or intolerable toxicity occurs.
Interventions
- DRUG Entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-12-13 |
| Est. Completion | 2021-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03211988
The ClinicalTrials.gov registry entry for NCT03211988 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Antonio Fojo, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Entinostat is the first listed.
NCT03211988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03211988 about?
NCT03211988 is a clinical study titled "Entinostat Neuroendocrine (NE) Tumor". This is an open-label, single arm, multi-center Phase II trial of entinostat given as a 5 mg oral dose every week (days 1, 8, 15, and 22 of a 4-week cycle) in patients with relapsed or refractory abdominal neuroendocrine (NE) tumors. Patients will continue on treatment until disease progression or i...
What is the current status of trial NCT03211988?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-12-13. Estimated completion is 2021-10-06.
What interventions are being tested in trial NCT03211988?
The interventions under investigation include: Entinostat (DRUG).
Who is sponsoring clinical trial NCT03211988?
This trial is sponsored by Antonio Fojo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.